Published in J Psychopharmacol on January 15, 2010
Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci (2013) 13.37
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab (2015) 1.63
An evolving scientific basis for the prevention and treatment of pediatric obesity. Int J Obes (Lond) (2014) 1.00
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol (2011) 0.98
Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry (2013) 0.88
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs (2015) 0.86
Drugs commonly associated with weight change: umbrella systematic review and meta-analysis (Protocol). Syst Rev (2012) 0.83
Pharmacotherapy for childhood obesity: present and future prospects. Int J Obes (Lond) (2012) 0.83
Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.80
Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. Child Adolesc Psychiatry Ment Health (2013) 0.80
Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome. Ther Clin Risk Manag (2015) 0.75
Metformin for Lithium-induced Weight Gain: A Case Report. Clin Psychopharmacol Neurosci (2016) 0.75
The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Res (2014) 0.75
Commentary: A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated with Initiation of Atypical Antipsychotic Therapy in Children and Adolescents. Front Psychiatry (2017) 0.75
The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79
Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clin Pharmacokinet (2014) 2.08
Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One (2013) 1.53
A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Pharmacogenomics (2012) 1.42
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost (2011) 1.35
Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study. BMJ Open (2012) 1.34
Statin treatment and mortality in bacterial infections--a systematic review and meta-analysis. PLoS One (2010) 1.05
What is a relevant statin concentration in cell experiments claiming pleiotropic effects? Br J Clin Pharmacol (2011) 1.00
Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol (2013) 0.95
The continuing challenge of providing drug information services to diminish the knowledge--practice gap in medical practice. Eur J Clin Pharmacol (2013) 0.88
Pharmacogenetics of anticoagulants. Hum Genomics Proteomics (2010) 0.84
Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives. Basic Clin Pharmacol Toxicol (2014) 0.82
Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study. Drug Metab Dispos (2013) 0.80
CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients. Pharmacogenomics (2013) 0.80
Increased liability of tramadol-warfarin interaction in individuals with mutations in the cytochrome P450 2D6 gene. Eur J Clin Pharmacol (2004) 0.80
Possible drug-drug interaction between quetiapine and lamotrigine--evidence from a Swedish TDM database. Br J Clin Pharmacol (2011) 0.79
Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Ther Drug Monit (2007) 0.78
Prevalence of Therapeutic Drug Monitoring for Antidepressants and Antipsychotics in Stockholm, Sweden: A Longitudinal Analysis. Ther Drug Monit (2015) 0.78
Direct and efficient liquid chromatographic-tandem mass spectrometric method for opiates in urine drug testing - importance of 6-acetylmorphine and reduction of analytes. Drug Test Anal (2013) 0.77
Comment: patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother (2003) 0.75
Severely diminished response to vitamin K-treatment for self-inflicted warfarin intoxication in a patient genotyped as CYP2C9*3*3. Eur J Clin Pharmacol (2009) 0.75
Extreme Duration of Diazepam-Associated Sedation in a Patient With Alcohol Delirium and CYP2C19 Polymorphisms. J Clin Psychopharmacol (2015) 0.75
Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype. Ther Drug Monit (2016) 0.75